NEJM reports ATOMIC: adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival in resected stage III mismatch repairdeficient colon cancer, with more grade 34 toxic effects mainly fatigue.
In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare